BAM
ZYNE

Blueshift Asset Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Blueshift Asset Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,632
Closed -$77K – 1360
2021
Q2 		$77K Buy
+14,632
New +$70.3K ﹤0.01% 880

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Blueshift Asset Management's ZYNE Position: Q3 2021 in Review

Blueshift Asset Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2021, closing a stake of 14,632 shares — an estimated $77K sold.

Blueshift Asset Management first reported a position in ZYNE in Q2 2021 and held it in 1 quarter. The position peaked at $77K in Q2 2021. 58 funds tracked by Wall St. Rank hold ZYNE as of Q3 2021.

  • Blueshift Asset Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 14,632 Zynerba Pharmaceuticals, Inc shares in Q3 2021, an estimated $77K.
  • Blueshift Asset Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Zynerba Pharmaceuticals, Inc position peaked at $77K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2021.

Based on Blueshift Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.